Combinatorial libraries of designed ankyrin repeat proteins (DARPins) have been proven to be a valuable source of specific binding proteins, as they can be expressed at very high levels and are very stable. We report here the selection of DARPins directed against a macromolecular multiprotein complex, the baseplate BppUxBppL complex of the lactococcal phage TP901-1. Using ribosome display, we selected several DARPins that bound specifically to the tip of the receptor-binding protein (RBP, the BppL trimer). The three selected DARPins display high specificity and affinity in the low nanomolar range and bind with a stoichiometry of one DARPin per BppL trimer. The crystal structure of a DARPin complexed with the RBP was solved at 2.1 A resolution. The DARPinxRBP interface is of the concave (DARPin)-convex (RBP) type, typical of other DARPin protein complexes and different from what is observed with a camelid VHH domain, which penetrates the phage p2 RBP inter-monomer interface. Finally, phage infection assays demonstrated that TP901-1 infection of Lactococcus lactis cells was inhibited by each of the three selected DARPins. This study provides proof of concept for the possible use of DARPins to circumvent viral infection. It also provides support for the use of DARPins in co-crystallization, due to their rigidity and their ability to provide multiple crystal contacts.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2781625 | PMC |
| http://dx.doi.org/10.1074/jbc.M109.037812 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DARPins as a novel tool to detect and degrade p73.
Cell Death Dis
December 2024
Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.
The concept of Targeted Protein Degradation (TPD) has been introduced as an attractive alternative to the development of classical inhibitors. TPD can extend the range of proteins that can be pharmacologically targeted beyond the classical targets for small molecule inhibitors, as a binding pocket is required but its occupancy does not need to lead to inhibition. The method is based on either small molecules that simultaneously bind to a protein of interest and to a cellular E3 ligase and bring them in close proximity (molecular glue) or a bi-functional molecule synthesized from the chemical linkage of a target protein-specific small molecule and one that binds to an E3 ligase (Proteolysis Targeting Chimeras (PROTAC)).
View Article and Find Full Text PDFHeterotelechelic Organometallic PEG Reagents Enable Modular Access to Complex Bioconjugates.
ACS Macro Lett
November 2024
Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California 90095, United States.
Article Synopsis
- - Organometallic oxidative addition complexes (OACs) are gaining attention as effective reagents for the selective modification of biomolecules by altering ligand and aryl properties to control reaction kinetics and regioselectivity.
- - Researchers explored the use of bidentate Au(III) OACs with bulky and electron-deficient aryl substrates to successfully achieve selective -arylation using computational and experimental methods.
- - The study successfully developed a protein-polymer OAC that performed rapid -arylation with designed ankyrin repeat proteins (DARPins) and various biologically relevant small molecules, paving the way for constructing complex biomolecular conjugates.
Phase I Clinical Evaluation of Designed Ankyrin Repeat Protein [Tc]Tc(CO)-(HE)-Ec1 for Visualization of EpCAM-Expressing Lung Cancer.
Cancers (Basel)
August 2024
Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.
A high level of EpCAM overexpression in lung cancer makes this protein a promising target for targeted therapy. Radionuclide visualization of EpCAM expression would facilitate the selection of patients potentially benefiting from such treatment. Single-photon computed tomography (SPECT) using Tc-labeled engineered scaffold protein DARPin Ec1 has shown its effectiveness in imaging tumors with overexpression of EpCAM in preclinical studies, providing high contrast just a few hours after injection.
View Article and Find Full Text PDFT-cell specific in vivo gene delivery with DART-AAVs targeted to CD8.
Mol Ther
October 2024
Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, 63225 Langen, Germany; Frankfurt Cancer Institute, Goethe University, 60596 Frankfurt, Germany. Electronic address:
One of the biggest challenges for in vivo gene therapy are vectors mediating highly selective gene transfer into a defined population of therapy-relevant cells. Here we present DARPin-targeted AAVs (DART-AAVs) displaying DARPins specific for human and murine CD8. Insertion of DARPins into the GH2/GH3 loop of the capsid protein 1 (VP1) of AAV2 and AAV6 resulted in high selectivity for CD8-positive T cells with unimpaired gene delivery activity.
View Article and Find Full Text PDFComputational design of newly engineered DARPins as HER2 receptor inhibitors for breast cancer treatment.
Res Pharm Sci
December 2023
Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Background And Purpose: Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 25% of breast cancer patients; therefore, its inhibition is a therapeutic target in cancer treatment.
Experimental Approach: In this study, two new variants of designed ankyrin repeat proteins (DARPins), designated EG3-1 and EG3-2, were designed to increase their affinity for HER2 receptors. To this end, DARPin G3 was selected as a template, and six-point mutations comprising Q26E, I32V, T49A, L53H, K101R, and G124V were created on its structure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!